Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer

A representative compound, BWA-522, effectively induced degradation of both androgen receptor-FL and androgen receptor-V7, and was more potent than the corresponding antagonist against prostate cancer cells in vitro.